替雷利珠单抗联合化疗治疗非小细胞肺癌的疗效及安全性的Meta分析  

Efficacy and safety of Tislelizumab combined with chemotherapy in the treatment of non-small cell lung cancer:a Meta-analysis

作　　者：王宽 谭笑 郭燕妮[3] WANG Kuan;TAN Xiao;GUO Yanni(School of Medical and Life Sciences,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China;Department of Respiratory and Critical Care Medicine,The Affiliated Hospital of Southwest Medical University,Luzhou 646099,Sichuan Province,China;Health Management Center,Yibin Second People’s Hospital of Sichuan Province,Yibin 644002,Sichuan Province,China)

机构地区：[1]成都中医药大学医学与生命科学学院,成都611137 [2]西南医科大学附属医院呼吸与危重症医学科,四川泸州646099 [3]宜宾市第二人民医院健康管理中心,四川宜宾644002

出　　处：《医学新知》2025年第4期442-451,共10页New Medicine

摘　　要：目的系统评价替雷利珠单抗联合化疗治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及安全性。方法计算机检索中国知网、万方、维普、PubMed、Embase、Web of Science等数据库中替雷利珠单抗联合化疗治疗NSCLC的研究,检索时限为建库起至2024年10月31日。采用RevMan 5.4软件及Stata 17软件进行Meta分析。结果共纳入18项研究,包括12项随机对照试验、6项队列研究,共计2209例患者。Meta分析结果显示,有效性方面,替雷利珠单抗联合化疗组的疾病完全缓解率[OR=2.96,95%CI(2.17,4.05)]、疾病部分缓解率[OR=1.89,95%CI(1.57,2.28)]、疾病控制率[OR=2.65,95%CI(2.12,3.31)]、疾病客观缓解率[OR=2.71,95%CI(2.26,3.25)]高于单独化疗组;疾病进展率[OR=0.33,95%CI(0.25,0.43)]、疾病稳定率[OR=0.79,95%CI(0.63,0.99)]低于单独化疗组。安全性方面,替雷利珠单抗联合化疗组的骨髓抑制发生率[OR=1.10,95%CI(0.74,1.64)]、胃肠道反应发生率[OR=0.99,95%CI(0.71,1.39)]、白细胞减少发生率[OR=1.04,95%CI(0.76,1.41)]、血小板减少发生率[OR=1.36,95%CI(1.00,1.84)]、肝肾功能损伤发生率[OR=1.02,95%CI(0.62,1.67)]与单独化疗组相比差异无统计学意义。结论替雷利珠单抗联合化疗治疗NSCLC的有效性优于单纯化疗,且安全性与单纯化疗无明显差异。Objective To evaluate the efficacy and safety of Tislelizumab combined with chemotherapy in the treatment of non-small cell lung cancer(NSCLC).Methods Studies about Tislelizumab combined with chemotherapy in the treatment of NSCLC were searched on CNKI,WanFang,VIP,PubMed,Embase,Web of Science from inception to October 31,2024.Meta-analysis was performed using RevMan 5.4 software and Stata 17 software.Results A total of 18 studies were included,including 12 randomized controlled trials and 6 cohort studies,with a total of 2,209 patients.The results of Meta-analysis showed that in terms of efficacy,the complete response rate[OR=2.96,95%CI(2.17,4.05)],partial response rate[OR=1.89,95%CI(1.57,2.28)],disease control rate[OR=2.65,95%CI(2.12,3.31)],and objective disease response rate[OR=2.71,95%CI(2.26,3.25)]of the Tislelizumab combined with chemotherapy group were higher than those of the chemotherapy group alone.The disease progression rate[OR=0.33,95%CI(0.25,0.43)]and stable disease rate[OR=0.79,95%CI(0.63,0.99)]were lower than those in the chemotherapy group alone.In terms of safety,there were no statistically significant differences in the incidences of bone marrow suppression[OR=1.10,95%CI(0.74,1.64)],gastrointestinal reactions[OR=0.99,95%CI(0.71,1.39)],leukopenia[OR=1.04,95%CI(0.76,1.41)],thrombocytopenia[OR=1.36,95%CI(1.00,1.84)],and liver and kidney function damage[OR=1.02,95%CI(0.62,1.67)]between the group treated with Tislelizumab combined with chemotherapy and the group treated with chemotherapy alone.Conclusion The efficacy of Tislelizumab combined with chemotherapy in the treatment of NSCLC is better than that of chemotherapy alone,and the safety is not significantly different from that of chemotherapy alone.

关 键 词：非小细胞肺癌 替雷利珠单抗 化疗 有效性 安全性 META分析 

分 类 号：R734.2[医药卫生—肿瘤]